Skip to main content

Table 2 Multilocus sequence types and antimicrobial efflux mechanisms in 2005 quinolone-resistant isolates

From: Rapid evolution of fluoroquinolone-resistant Escherichia coli in Nigeria is temporally associated with fluoroquinolone use

QREC Strain

MLST ST

ST Complex

fliC type

Resistance

Profile

Nalidixic acid MIC (μg/ml)

Organic solvent tolerance

Nalidixic acid fold inhibition with PAβN

Δ GyrA

Δ ParC

Transcription fold change-tolC

Efflux pump genes with transcription fold change ≥ 4

Efflux regulator genes with transcription fold change 2-8

Efflux regulator genes with transcription fold change > 8

01A

10

10

A

A NSLTR

32

+

4

S83L

-

2.0

emrK

-

rob

05C

10

10

B

NS TR

4

++

8

-

-

1.0

mdtA

-

-

23A

10

10

B

AC NSLTR

4

++

8

-

-

2.0

mdtA

marA, soxS, beaS, marR, acrR

-

33A

10

10

B

AC NSLTR

4

++

8

-

-

4.5

acrA, acrD, acrE, bcr, cusB, emrA, emrD, emrK, fsr,

marA, soxS, evgA, marR, acrR

rob, baeS

25A

10

10

D

A NSLTR

4

++

8

-

-

16.8

acrA, acrD, acrE, bcr, cusB, emrA,emrD, emrK, fsr, macA, mdfA, mdtA

evgA

marA, soxS, rob, beaS, marR, acrR

40B

10

10

E

N

4

+++

8

-

-

1.0

-

-

-

16A

34

10

E

NS

4

+++

16

-

-

4.2

acrA, acrD, acrE, bcr, cusB, fsr, mdtA

marA, soxS, rob, marR, acrR

baeS

49A

43

10

F

N

4

+

8

S83L

-

2.2

-

-

-

23B

10

10

C

C N LTR

4

 

8

-

-

2.2

-

-

-

31A

494

none

C

A NSLTR

4

++

8

-

-

2.2

acrD, acrE, bcr, emrA, mdtA

baeS

-

38C

521

none

C

NS R

4

++

8

-

-

4.3

acrA, acrD, acrE, bcr, cusB, emrA, emrD, fsr, mdfA, mdtA

marA, soxS, evgA, rob, marR, acrR

beaS,

22A

452

none

C

NSLTR

4

+

8

-

-

1.1

-

-

-

31B

452

none

C

NSLTR

4

-

4

-

-

2.5

-

-

-

33B

504

none

K

NSLT

1024

+++

16

S83L

-

1.0

-

-

-

34B

498

467

G

NS

4

++

8

-

-

2.1

-

baeS

-

32C

503

13

H

NSLTR

4

++

8

-

-

1.0

-

baeS

-

30A

156

156

I

AC NSLTR

4

++

16

-

-

4.3

acrA, acrD, cusB, emrA, emrK, mdfA

soxS, baeS

-

27A

448

448

J

ACPNSLTR

1024

+++

2

S83L, D87N

S80I

33.2

acrA, acrD, acrE, bcr, cusB, emrA, emrD, fsr, macA, mdfA, mdtA

-

marA, soxS, evgA, rob, beaS, marR, acrR

09C

517

none

L

AC NSLTR

4

++

8

-

-

8.6

acrA, acrD, acrE, bcr, cusB, emrA,emrD, emrK, fsr, mdfA, mdtA

marA, soxS, evgA, rob, marR, acrR

beaS

38A

517

none

N

A NSLTR

4

++

8

-

-

4.2

acrR, acrD, acre, bcr, cusB, fsr, mdtA

marA, soxS, evgA, rob, baeS, marR, acrR

 

ATCC 25922

ND

ND

ND

-

2

-

8

ND

ND

0.4

-

-

-

NCTC10418

ND

ND

ND

-

2

-

4

ND

ND

2.1

-

-

-

  1. ND: Not Determined
  2. Antimicrobials: A, ampicillin; C, chloramphenicol; P, ciprofloxacin; N, nalidixic acid; S, streptomycin; L, sulfonamides; T, tetracycline; R, trimethoprim
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us